NEW YORK (GenomeWeb) – Although Myriad Genetics' forecasted revenues for fiscal year 2017 fell short of Wall Street's expectations, the company yesterday outlined its plan for diversifying its product portfolio and achieving long-term growth.
The company reported FY2016 revenues of $753.8 million, a 4 percent increase from the prior year, and said it is expecting revenues of between $740 million to $760 million in FY2017. Analysts were expecting $755.5 million in revenues for FY2016 and had modeled $788.9 million for the coming 12 months.